Workflow
MENON(301156)
icon
Search documents
美农生物(301156) - 董事会薪酬与考核委员会关于2025年限制性股票激励计划授予日激励对象名单的核查意见
2025-07-22 11:14
上海美农生物科技股份有限公司 (5)法律法规规定不得参与上市公司股权激励的情形; (6)中国证监会认定的其他情形。 2、本激励计划授予激励对象符合《公司法》《证券法》等法律法规和规范 性文件以及《公司章程》规定的任职资格,符合《管理办法》《上市规则》等法 律法规和规范性文件规定的激励对象条件,符合本激励计划规定的激励对象范围。 董事会薪酬与考核委员会关于 2025 年限制性股票激励计划 授予日激励对象名单的核查意见 上海美农生物科技股份有限公司(以下简称"公司")董事会薪酬与考核委 员会依据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民 共和国证券法》(以下简称"《证券法》")、《上市公司股权激励管理办法》 (以下简称"《管理办法》")、《深圳证券交易所创业板股票上市规则》(以 下简称"《上市规则》")、《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》(以下简称"《自律监管指南》")等相关法律法规、规范 性文件和《公司章程》的有关规定,对公司 2025 年限制性股票激励计划(以下 简称"本激励计划")授予日激励对象名单进行审核,发表核查意见如下: 1、本激励计划授予激励对象符 ...
美农生物(301156) - 上海荣正企业咨询服务(集团)股份有限公司关于上海美农生物科技股份有限公司2025年限制性股票激励计划授予事项之独立财务顾问报告
2025-07-22 11:14
证券简称:美农生物 证券代码:301156 上海荣正企业咨询服务(集团)股份有限公司 关于 上海美农生物科技股份有限公司 2025 年限制性股票激励计划 授予事项 独立财务顾问报告 2025 年 7 月 | 一、释义 | 3 | | --- | --- | | 二、声明 | 5 | | 三、基本假设 | 6 | | 四、本激励计划的审批程序 | 7 | | 五、本次实施的限制性股票股权激励计划与股东会审议通过的限制性股票激励 | | | 计划差异情况 | 9 | | 六、本激励计划的授予情况 | 10 | | 七、本次限制性股票授予条件成就情况的说明 | 11 | | 八、实施本次激励计划对相关年度财务状况和经营成果影响的说明 13 | | | 九、独立财务顾问的核查意见 | 14 | | 十、备查文件及咨询方式 | 15 | | (一)备查文件 | 15 | | (二)咨询方式 | 15 | 一、释义 本独立财务顾问报告中,以下词语如无特殊说明,在本文中具有如下含义: | 简称 | | 释义 | | --- | --- | --- | | 美农生物、公司、上市 公司 | 指 | 上海美农生物科技股份有限公司 ...
美农生物(301156) - 上海美农生物科技股份有限公司投资者关系活动记录表20250715
2025-07-15 12:07
Group 1: International Business Development - The company has established a sales network in over 40 countries and regions, including Vietnam, Russia, Thailand, and Brazil, adhering to a "deepening domestic and breaking through overseas" market strategy [2][3]. - In the first half of 2025, the company reported a year-on-year growth of over 20% in overseas business revenue for both 2023 and 2024 [4]. Group 2: Corn Protein Processing Project - The company is constructing a corn protein processing project with an annual capacity of 100,000 tons, expected to be completed in 2025 [5]. - Once fully operational, the project will provide 100,000 tons of corn protein products annually, contributing significantly to the global feed industry and generating new revenue streams for the company [5]. Group 3: Product Applications and Advantages - The corn protein products will primarily serve the poultry and aquaculture sectors, diversifying the company's product strategy to mitigate market volatility risks [6][7]. - The project utilizes local corn by-products, enhancing the nutritional value of corn protein through enzymatic hydrolysis, which improves digestibility and absorption [7]. Group 4: Competitive Advantages - The company's core competitive advantages are reflected in three dimensions: product innovation, market management, and talent development [8][9][10]. - The company emphasizes a "full nutrition" product strategy, leveraging proprietary technologies to cater to different animal growth stages and market needs [8]. Group 5: Future Business Plans - The company is exploring opportunities in the pet food and feed sectors, having established partnerships with companies like Fubei [11]. - The company maintains a focus on managing accounts receivable and credit risk through differentiated credit policies and enhanced customer management [12]. Group 6: Digital Transformation - The company has implemented an ERP system and smart manufacturing systems to enhance operational efficiency and customer satisfaction [14]. - The integration of sales, procurement, and production plans aims to improve information accuracy and workflow efficiency [14].
美农生物(301156) - 董事会薪酬与考核委员会关于2025年限制性股票激励计划激励对象名单的公示情况说明及核查意见
2025-07-15 09:36
上海美农生物科技股份有限公司 董事会薪酬与考核委员会关于 2025 年限制性股票激励计划 激励对象名单的公示情况说明及核查意见 2025 年 7 月 3 日,上海美农生物科技股份有限公司(以下简称"公司")召 开第五届董事会第十二次会议,审议通过了《关于公司〈2025 年限制性股票激励 计划(草案)〉及其摘要的议案》等相关议案,根据《上市公司股权激励管理办法》 (以下简称"《管理办法》")、《深圳证券交易所创业板股票上市规则》(以下 简称"《上市规则》")、《深圳证券交易所创业板上市公司自律监管指南第 1 号 ——业务办理》(以下简称"《自律监管指南》")和《上海美农生物科技股份有 限公司章程》(以下简称"《公司章程》")的相关规定,公司对 2025 年限制性 股票激励计划(以下简称"本次激励计划")拟激励对象的姓名和职务在公司内部 进行了公示,公司董事会薪酬与考核委员会(以下简称"薪酬与考核委员会")结 合公示情况对激励对象名单进行核查,相关公示情况及核查意见说明如下: 一、公示情况及核查方式 1、公司对激励对象名单的公示情况 公司于 2025 年 7 月 3 日公开披露了《2025 年限制性股票激励计划( ...
美农生物(301156) - 关于完成工商变更登记并换发营业执照的公告
2025-07-11 08:40
证券代码:301156 证券简称:美农生物 公告编号:2025-043 上海美农生物科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 上海美农生物科技股份有限公司(以下简称"公司")于 2025 年 4 月 24 日 召开第五届董事会第十一次会议、2025 年 5 月 16 日召开 2024 年年度股东大会, 分别审议通过了《关于变更注册资本及修订<公司章程>的议案》。公司股东会授 权公司经营管理层具体办理工商变更登记、《公司章程》备案并签署相关文件, 具体内容详见公司在巨潮资讯网(www.cninfo.com.cn)披露的相关公告。 近日,经上海市市场监督管理局核准,公司完成了相关工商变更登记和《公 司章程》备案手续,并取得了换发的《营业执照》,现将变更后的登记情况公告 如下: 一、《营业执照》的基本信息 1、名称:上海美农生物科技股份有限公司 2、统一社会信用代码:9131000063081624X7 3、类型:股份有限公司(上市、自然人投资或控股) 4、法定代表人:洪伟 5、注册资本:人民币 14078.4675 万元整 8、经营范围:从事生物技术领域内的技术开发、技术转让、技术咨询、技 术服 ...
减持速报 | 通宇通讯(002792.SZ)澳籍实控人时桂清拟减持近3%,光环新网(300383.SZ)多高管拟集体减持
Xin Lang Cai Jing· 2025-07-08 01:25
Group 1 - *ST San Sheng (002742.SZ): The controlling shareholder Pan Xianwen's 32.2 million shares have been transferred, accounting for 7.30% of the total share capital, reducing his holding from 17.26% to 16.75, with no change in company control [1] - Aikang Co., Ltd. (300889.SZ): Shareholders Zhang Fengbin and Feng Renrong reduced their holdings by a total of 1.76 million shares, accounting for 1.06% of the total share capital, completing the reduction plan [1] - Allianz Ruishi (301042.SZ): Director Shen Lei reduced his holdings by 98,700 shares, accounting for 0.14% of the total share capital, with the reduction plan period ending [1] Group 2 - Baotong Technology (300031.SZ): Controlling shareholder Bao Zhifang and director Tang Yu plan to reduce their holdings by up to 8.3749 million shares and 1.526988 million shares, accounting for no more than 2% and 0.36% of the total share capital, respectively [2] - Biyiwei (688045.SH): Shareholders Fang Guang Erqi and Yuan Chengjun plan to reduce their holdings by up to 139,680 shares and 69,840 shares, accounting for no more than 2% and 1% of the total share capital, respectively [2] - Chahua Co., Ltd. (603615.SH): Shareholder Shenzhen Hanjinliang reduced 2.397 million shares, accounting for 0.99% of the total share capital, completing the reduction plan [2] Group 3 - Dacai Co., Ltd. (605287.SH): Shareholder Qingdao Dikuang Chanquan Development Co., Ltd. reduced 3.64 million shares, accounting for 2.60% of the total share capital, completing the reduction plan [3] - Dize Pharmaceutical (688192.SH): Vice President Zhang Shiying reduced 161,550 shares, accounting for 0.0035% of the total share capital, completing the reduction plan [3] - Fuhan Micro (300613.SZ): Controlling shareholder's concerted action party plans to reduce up to 6.90208 million shares, accounting for 3% of the total share capital [3] Group 4 - Guanghuan Xinwang (300383.SZ): Directors and vice presidents plan to reduce a total of up to 720,476 shares, accounting for no more than 0.04% of the total share capital [4] - Hanyu Group (300403.SZ): Director and Vice President Wu Geming plans to reduce up to 1 million shares, accounting for 0.1658% of the total share capital [4] - Haosen Intelligent (688529.SH): Shareholders plan to reduce a total of up to 3 million shares, accounting for 1.7838% of the total share capital [4] Group 5 - Huilong New Materials (301057.SZ): Controlling shareholder's concerted action party plans to reduce up to 3.482902 million shares, accounting for 3% of the total share capital excluding repurchased shares [5] - Huitong Co., Ltd. (688219.SH): Shareholder Tong'an Fund reduced 4.667815 million shares, accounting for 0.93% of the total share capital, completing the reduction plan [5] Group 6 - Jiangsu Shentong (002438.SZ): Shareholder Huzhou Fenglin Huoshan Equity Investment Partnership reduced a total of 14.205 million shares, accounting for 2.798808% of the total share capital, completing the reduction plan [6] - Jiangtian Chemical (300927.SZ): Shareholder Jiangshan Co., Ltd. reduced 1.3265 million shares, accounting for 0.92% of the total share capital [6] - Jin Sanjiang (301059.SZ): Shareholder Guangzhou Saina reduced 104,900 shares, accounting for 0.05% of the total share capital, completing the reduction plan [6] Group 7 - Jingxue Energy (301010.SZ): Controlling shareholder's concerted action party reduced 1.08 million shares, accounting for 1% of the total share capital, completing the reduction plan [7] - Jiuwu High-Tech (300631.SZ): Vice President Wang Xiaohu and Cheng Junjun plan to reduce up to 18,900 shares and 5,000 shares, accounting for no more than 0.1511% and 0.04% of the total share capital, respectively [7] - Kanghui Pharmaceutical (603139.SH): Shareholder Shanghai Sailoxian plans to reduce up to 2.9964 million shares, accounting for 3% of the total share capital [7] Group 8 - Meino Biological (301156.SZ): Shareholder's concerted action party reduced 1.297029 million shares, accounting for 0.92% of the total share capital, completing the reduction plan [8] - Minfa Aluminum Industry (002578.SZ): Shareholder Huang Tianhuo reduced 6.6702 million shares, accounting for 0.71% of the total share capital, reducing his holding to 4.9963% [8] - Nuo Puxin (002215.SZ): Directors and senior management plan to reduce a total of up to 1.8607 million shares, accounting for no more than 0.185% of the total share capital [8] Group 9 - Entropy Technology (301330.SZ): Shareholders reduced a total of 4,693,864 shares, accounting for 1.9556% of the total share capital, completing the reduction plan [9] - Shengbang Co., Ltd. (301233.SZ): Supervisor Hu Jilin plans to reduce up to 5,650 shares, accounting for 0.0111% of the total share capital [9] - Shudao Equipment (300540.SZ): Senior management did not reduce their shares, and the reduction plan period has ended [9] Group 10 - Tongyu Communications (002792.SZ): Controlling shareholder and actual controller Shi Guiqing plans to reduce up to 15,653,487 shares, accounting for 2.9963% of the total share capital [10] Group 11 - Wuzhou Xinchun (603667.SH): Senior management plans to reduce a total of up to 22,500 shares, accounting for no more than 0.0061%, 0.0067%, and 0.0037% of the total share capital [11] - New Sharp Co., Ltd. (688257.SH): Senior management plans to reduce up to 750,000 shares, accounting for no more than 0.2971% of the total share capital [11] - New Hope (000876.SZ): Senior management reduced 225,000 shares, accounting for 0.005% of the total share capital, completing the reduction plan [11] Group 12 - Youke De (688158.SH): Shareholder Zhongyi Capital reduced 882,766 shares, accounting for 0.19% of the total share capital, completing the reduction plan [12] - Changqing Technology (001324.SZ): Shareholders reduced a total of 4,165,050 shares, accounting for 3.00% of the total share capital, completing the reduction plan [12] - Changxin Bochuang (300548.SZ): Shareholders plan to reduce up to 8.6 million shares, accounting for 2.95% of the total share capital [12] Group 13 - Zhongfu Industrial (600595.SH): Shareholder Henan Yicheng Chuangtou plans to reduce up to 40 million shares, accounting for 1% of the total share capital [13] - Zhuhai Ming Technology (300232.SZ): Controlling shareholder Lin Mingfeng plans to reduce up to 21,722,009 shares, accounting for 1.99% of the total share capital [13] - Zhuoyi Information (688258.SH): Employee shareholding platform plans to reduce up to 2,271,445 shares, accounting for no more than 1.88% of the total share capital [13]
美农生物(301156) - 关于持股5%以上股东的一致行动人减持股份计划期限届满暨实施结果的公告
2025-07-07 10:22
减持股份计划期限届满暨实施结果的公告 证券代码:301156 证券简称:美农生物 公告编号:2025-042 上海美农生物科技股份有限公司 关于持股 5%以上股东的一致行动人 公司股东唐旭保证向本公司提供的信息内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 上海美农生物科技股份有限公司(以下简称"公司")于 2025 年 3 月 14 日 披露了《关于持股 5%以上股东的一致行动人减持股份计划的预披露公告》(公告 编号:2025-010),公司持股 5%以上股东唐凌的一致行动人唐旭计划自减持计划 预披露公告披露之日起 15 个交易日后的 3 个月内以集中竞价和大宗交易方式合 计减持其持有的公司股份不超过 1,407,846 股(即不超过公司总股本的 1%)。 公司近日收到唐旭出具的《关于持有上海美农生物科技股份有限公司股份减 持计划期限届满暨实施结果的告知函》,获悉唐旭通过集中竞价方式累计减持公 司股份 1,297,029 股,占公司总股本的 0.92%。本次减持计划实施完毕。 根据《中华人民共和国证券法》《深圳证券交易所上市 ...
美农生物: 股权激励计划自查表
Zheng Quan Zhi Xing· 2025-07-03 16:26
Core Viewpoint - Shanghai Meino Biological Technology Co., Ltd. is undergoing a review of its stock incentive plan to ensure compliance with relevant regulations and to protect the interests of shareholders [1][2][3]. Compliance with Listing Company Requirements - The financial report for the most recent accounting year did not receive a negative opinion or inability to express an opinion from the registered accountant [1]. - There have been no instances in the last 36 months where profit distribution did not comply with laws, regulations, or company articles [1]. Compliance of Incentive Objects - The incentive plan does not include shareholders or actual controllers holding more than 5% of the company's shares [1]. - No significant violations leading to administrative penalties from the China Securities Regulatory Commission (CSRC) have occurred in the last 12 months [1]. Compliance of Incentive Plan - The total number of shares involved in all effective stock incentive plans does not exceed 20% of the company's total equity [1]. - The reserved rights for incentive objects do not exceed 20% of the proposed rights to be granted in this stock incentive plan [1]. Disclosure Completeness of Incentive Plan - The plan's purpose, criteria for determining incentive objects, and the range of those objects have been clearly stated [1]. - The number of rights to be granted and their percentage of the company's total equity have been disclosed, including any reserved rights [1]. - The plan includes details on the effective period, authorization date, and lock-up arrangements [1]. Performance Assessment Indicators - Performance assessment indicators are objective, public, clear, and beneficial for enhancing the company's competitiveness [4]. - At least three comparable companies from the same industry have been selected for benchmarking [4]. Compliance of Lock-up and Vesting Periods - The interval between the authorization date of restricted stock and the first lifting of restrictions is not less than one year [4]. - The proportion of stock options that can be exercised in each period does not exceed 50% of the total stock options granted to the incentive objects [4]. Professional Opinions and Legal Compliance - The remuneration and assessment committee has provided opinions on whether the stock incentive plan benefits the company's sustainable development [4]. - The company has engaged a law firm to issue a legal opinion in accordance with the Stock Incentive Management Measures [4].
美农生物: 第五届董事会第十二次会议决议公告
Zheng Quan Zhi Xing· 2025-07-03 16:26
Group 1 - The company held its 12th meeting of the 5th Board of Directors on July 3, 2025, with all 7 directors present, ensuring compliance with relevant laws and regulations [1] - The Board approved the draft of the 2025 Restricted Stock Incentive Plan to attract and retain talent while aligning the interests of shareholders, the company, and employees [1][2] - The plan aims to establish a long-term incentive mechanism and requires approval from the shareholders' meeting with a two-thirds majority [2][3] Group 2 - The Board also approved the implementation assessment management measures for the 2025 Restricted Stock Incentive Plan, which will be disclosed on the same day [2][3] - The Board proposed to authorize itself to handle various matters related to the implementation of the incentive plan, including determining eligibility and adjusting stock grants [4][5] - A temporary shareholders' meeting is scheduled for July 22, 2025, to further discuss the incentive plan [6]
美农生物: 董事会薪酬与考核委员会关于公司2025年限制性股票激励计划相关事项的核查意见
Zheng Quan Zhi Xing· 2025-07-03 16:26
Core Viewpoint - The Shanghai Meino Biological Technology Co., Ltd. has proposed a restricted stock incentive plan for 2025, which has been reviewed and deemed eligible for implementation by the Board of Directors' Compensation and Assessment Committee [1][3]. Group 1: Eligibility and Compliance - The company meets the qualifications to implement the stock incentive plan as there have been no negative or unqualified audit opinions on the financial reports for the last accounting year [1]. - The incentive plan does not include independent directors, and all selected incentive objects comply with the conditions set forth in the relevant regulations [2]. Group 2: Disclosure and Approval Process - The company is required to publicly disclose the names and positions of the incentive objects for at least 10 days prior to the shareholders' meeting [3]. - The plan's details, including grant arrangements and conditions, must be reviewed and approved by the shareholders' meeting before implementation [3]. Group 3: Objectives and Benefits - The incentive plan aims to align the interests of employees and shareholders, enhance management efficiency, and support the sustainable development of the company [3].